BNR Burning Rock Biotech Ltd Annual reports only
Services-Medical Laboratories · Nasdaq · SEC CIK 1792267
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 · USD | FY20242024-12-31 · CNY | FY20232023-12-31 · CNY | FY20222022-12-31 · USD | FY20212021-12-31 · CNY |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $77.16M | 515.82M | 537.43M | $81.66M | 507.86M |
| Cost of revenue | $19.54M | 153.42M | 174.21M | $26.56M | 143.72M |
| Gross profit | $57.62M | 362.40M | 363.23M | $55.10M | 364.15M |
| R&D expense | $23.81M | 232.29M | 347.02M | $61.16M | 367.86M |
| SG&A expense | $18.03M | 261.64M | 437.82M | $82.39M | 490.26M |
| Operating income | -$7.84M | -357.56M | -669.32M | -$142.15M | -797.06M |
| Interest expense | — | — | — | — | 1.54M |
| Pretax income | -$7.69M | -340.74M | -651.30M | -$140.53M | -795.80M |
| Income tax | $223,000 | 5.88M | 2.39M | $288,000 | 899,000 |
| Net income | -$7.92M | -346.63M | -653.69M | -$140.81M | -796.70M |
| EBITDA | -$4.73M | -305.36M | -535.92M | -$124.15M | -749.30M |
| EPS (basic) | — | — | — | — | 0.00 |
| EPS (diluted) | — | — | — | — | 0.00 |
| Weighted avg. shares (diluted) | — | — | — | — | 0 |
| Banking | |||||
| Net interest income | -$4,000 | 0 | 0 | $15,000 | -1.54M |
| Balance sheet | |||||
| Cash & equivalents | $68.41M | 519.85M | 615.10M | $130.32M | 1.44B |
| Short-term investments | — | — | — | $0 | 63.76M |
| Receivables | $24.25M | 152.01M | 126.86M | $15.94M | 92.20M |
| Inventory | $6.95M | 53.76M | 69.02M | $18.89M | 123.21M |
| Current assets | $105.62M | 776.62M | 884.10M | $182.50M | 1.82B |
| PP&E, net | $4.45M | 47.15M | 131.91M | $36.51M | 325.44M |
| Intangibles | $41,000 | 421,000 | 964,000 | $288,000 | 5.15M |
| Total assets | $117.31M | 885.30M | 1.04B | $230.16M | 2.28B |
| Current liabilities | $35.32M | 266.30M | 263.36M | $59.66M | 372.18M |
| Short-term debt | — | — | — | $0 | 2.37M |
| Long-term debt | $243,000 | 0 | — | — | — |
| Total debt | $243,000 | 0 | — | — | — |
| Total liabilities | $40.77M | 304.48M | 271.59M | $62.22M | 433.28M |
| Shareholders' equity | $76.54M | 580.83M | 768.41M | $167.94M | 1.85B |
| Net debt | -$68.17M | -519.85M | — | — | — |
| Cash flow statement | |||||
| Operating cash flow | -$4.07M | -92.26M | -255.78M | -$66.23M | -477.89M |
| Capital expenditure | $751,000 | 5.42M | 8.10M | $8.99M | 204.33M |
| Free cash flow | -$4.82M | -97.68M | -263.89M | -$75.23M | -682.22M |
| Investing cash flow | -$628,000 | -4.41M | -9.30M | -$1.08M | 81.70M |
| Financing cash flow | $272,000 | -72,000 | -48.83M | -$12.50M | -52.90M |
| Depreciation & amortization | $3.11M | 52.20M | 133.40M | $17.99M | 47.77M |
| Stock-based compensation | $1.98M | 155.62M | 260.72M | $47.38M | 282.43M |
| Share buybacks | — | — | — | — | 0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.